
Oncology Trial Protocol & Patient Safety Documentation
Generate compliant oncology trial protocols and safety records
What You Can Do
You can rapidly create regulatory-compliant oncology trial documentation including detailed protocols, patient safety assessments, and adverse event records. This skill ensures your trial materials meet FDA and ICH-GCP standards, reducing compliance risk and accelerating trial setup. Generate enrollment workflows, informed consent forms, and Data Safety Monitoring Board plans tailored to your specific oncology study.
Features
Creates comprehensive trial protocols with study design, objectives, enrollment criteria, visit schedules, and statistical considerations aligned with regulatory standards
Generates adverse event reports, severity grading using CTCAE criteria, and safety monitoring templates with proper expedited reporting procedures
Validates documentation against FDA and ICH-GCP guidelines, identifying gaps and suggesting corrections before regulatory submission
Develops detailed inclusion/exclusion criteria, clinical decision trees, and enrollment screening checklists specific to your cancer type and patient population
Drafts patient-friendly informed consent forms with appropriate risk/benefit language and regulatory disclosures
Creates Data Safety Monitoring Board charters, stopping rules, and safety reporting procedures for ongoing trial oversight
Generates validation rules, audit trails, and data integrity checklists ensuring completeness and accuracy in trial documentation
Example Output
Generated Protocol Section
Study Title: A Phase 2 Randomized Trial of [Drug] in Advanced [Cancer Type] Patients
Primary Objective: Assess objective response rate (ORR) per RECIST 1.1 criteria
Inclusion Criteria:
- Histologically or cytologically confirmed [cancer type]
- Age ≥18 years
- ECOG performance status 0–1
- Adequate organ function: AST/ALT ≤3× ULN, creatinine ≤1.5× ULN
- Prior treatment: At least 4 weeks from last chemotherapy
Safety Monitoring:
- Serious adverse events reported within 24 hours
- Grade 3+ hematologic AEs reported within 5 business days
- Expedited review for deaths or treatment-related hospitalizations
Adverse Event Severity Grading: CTCAE v5.0 applied to all laboratory and clinical assessments
Visit Schedule:
- Screening (Day -14 to Day 1)
- Baseline labs & imaging (Day 1)
- On-treatment safety visits: Weeks 2, 4, 8, 12, then every 8 weeks
- End-of-treatment assessment within 7 days of last dose
What's Included
- Protocol Templates: Pre-built templates for Phase 1, 2, and 3 oncology trials with sections for design rationale, statistical analysis plans, and regulatory language
- Safety Documentation Suite: Adverse event forms, CTCAE severity grading tools, expedited reporting procedures, and safety monitoring checklists
- Regulatory Compliance Checklist: FDA Form 1571/1572 and ICH-GCP alignment verification to confirm all critical requirements before submission
- Enrollment & Eligibility Tools: Patient screening tools, eligibility decision trees, enrollment justification documents, and enrollment tracking templates
- Informed Consent Framework: Template ICF with sections on study purpose, procedures, risks/benefits, privacy protections, and withdrawal instructions
- DSMB Charter & Safety Plans: Data Safety Monitoring Board charter, interim analysis plans, stopping rules, and escalation procedures for safety concerns
Who It's For
- Clinical Trial Coordinators
- Oncologists & Principal Investigators
- Clinical Research Monitors
- Regulatory Affairs Specialists
- Medical Safety Officers
Best For
- Protocol Development & Trial Setup
- Safety Documentation & Adverse Event Management
- Regulatory Compliance Verification
- Patient Enrollment & Eligibility Workflows
- Data Integrity & Quality Assurance







